Joëlle Chabry
Université Côte d'Azur, Institute of Molecular and Cellular Pharmacology, France
Title: Potential therapeutic of the adipokine Adiponectin as antidepressant
Biography
Biography: Joëlle Chabry
Abstract
Epidemiological data indicate high comorbidity between metabolic and psychiatric disorders, particularly obesity and depression. Using a well-characterized anxiety/depressive-like mouse model consisting of continuous input of corticosterone for several consecutive weeks, we investigate the metabolic changes including weight, adiposity and plasma biological parameters (lipids, adipokines, and cytokines). In parallel, a panel of reliable behavioral tests was conducted to assessing numerous facets of the depression-like state, including anxiety, resignation, reduced motivation, loss of pleasure and social withdrawal. Our data show that chronic administration of corticosterone induced the parallel onset of metabolic and behavioral dysfunctions in mice. Potent adiponectin receptor agonists, prevented the corticosterone-induced early onset of moderate obesity and metabolic syndromes as well as successfully reversed the depression-like state. The possible mechanisms of actions of adiponectin receptor agonists have been deeply investigate as well as the routes of delivery, the dose-response and the side effects in three different mouse models of anxiety/depression-like. Our study highlights the pivotal role of the adiponergic system in the development of both metabolic and psychiatric disorders. Because about one third of depressive patients are resistant to currently available antidepressants, Adiponectin receptor agonists may constitute a novel and promising class of antidepressants.